Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting
– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that four abstracts evaluating PEDMARK® (sodium thiosulfate injection) were accepted […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.